Renal Function Difference Between Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy and HBIG Combined With Entecavir in Liver Recipients

J. Lee,^1,2 J. Lee,^1,2 J. Lee,³ M. Kim,^1,2 M. Ju,^1,2 G. Choi,^1,2 J. Choi,^1,2 S. Kim,^1,2 D. Joo.^1,2

¹Department of Transplantation Surgery, Severance Hospital, Yonsei University Health System, Seroul, Korea
²Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea
³Department of Surgery, CHA Bundang Medical Center, CHA University, Bundang, Korea.

Meeting: 2015 American Transplant Congress

Abstract number: B146

Keywords: Liver transplantation, Nephrotoxicity, Prophylaxis, Renal dysfunction

Session Information

Session Name: Poster Session B: Liver - Kidney Issues in Liver Transplantation

Session Type: Poster Session

Date: Sunday, May 3, 2015

Session Time: 5:30pm-6:30pm

Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Background: To reduce the HBV reinfection after liver transplantation, anti-hepatitis B immunoglobulin (HBIG) alone or combination with antiviral nucleotide analogues are usually used regimen. However, antiviral nucleotide analogues have nephrotoxicity, which is a critical issue because renal dysfunction frequently happens after liver transplantation.

Method: Medical records of 191 liver recipients with HBV who underwent liver transplantation between Sep 2005 and Dec 2012 were retrospectively reviewed. The difference of renal function of HBIG mono-therapy group (HBIG) and HBIG combined with Entecavir group (HBIG+ETV) were analyzed.

Results: There was no significant difference in age, gender, body mass index, intraoperative blood loss, and MELD score between the two groups. But the patients who had preoperative ascites, mean preoperative AST level, preoperative GFR level, and the applying event of CRRT were significantly different between the groups. The GFR by calculated Crockroft-Gaut, MDRD and CKD-EPI were significantly more decreased in HBIG+ ETV group than HBIG mono group at 5 years after LT

Conclusion: There was no difference of recurrence rate of HBV. However, HBIG+ETV combination regimen showed more declination of eGFR in long-term period after liver transplantation than HBIG alone.

To cite this abstract in AMA style:

Lee J, Lee J, Lee J, Kim M, Ju M, Choi G, Choi J, Kim S, Joo D. Renal Function Difference Between Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy and HBIG Combined With Entecavir in Liver Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-function-difference-between-anti-hepatitis-b-immunoglobulinhbig-monotherapy-and-hbig-combined-with-entecavir-in-liver-recipients/. Accessed November 24, 2024.

« Back to 2015 American Transplant Congress